A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.

Abstract

The administration of tumor lysate-pulsed DCs is nontoxic and capable of inducing immunological response to tumor antigen. Additional studies are necessary to improve tumor rejection responses.